Status:
COMPLETED
Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency
Lead Sponsor:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Conditions:
Migraine, Hemicrania
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat. The literature of the last ...
Detailed Description
Background and significance Medication Overuse Headache (MOH) is a disabling pain syndrome with a prevalence of 2% in the general population, and which affects patients suffering from primary headache...
Eligibility Criteria
Inclusion
- age \>18 yrs diagnosis of MOH and CM (1) written informed consent
Exclusion
- co-existent severe medical or psychiatric illnesses, documented by specific previous diagnoses seizures use of opioids
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04410536
Start Date
June 15 2020
End Date
July 31 2022
Last Update
January 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit
Milan, Milano, Italy, 20133